-
Novartis Pharmaceuticals Corporation et al v. Noven Pharmaceuticals Inc. DC CAFC
- 1:13-cv-00527
- D. Del.
- Judge: Richard G. Andrews
- Filed: 04/03/2013
- Closed: 09/14/2015
- Latest Docket Entry: 04/28/2016
- PACER
- Docket updated daily
5
Plaintiffs
3
Defendants
1
Accused
Product
2
Patents-in-Suit
895
Days in
Litigation
-
Novartis Pharmaceuticals Corporation et al v. Noven Pharmaceuticals Inc. DC CAFC
- 1:13-cv-00527
- D. Del.
- Judge: Richard G. Andrews
- Filed: 04/03/2013
- Closed: 09/14/2015
- Latest Docket Entry: 04/28/2016
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 7 |
A transdermal device comprising a pharmaceutical composition as defined in claim 1, wherein the pharmaceutical composition is supported by a substrate.
|
Invalid (103)
Entry 75 |
| 16 |
A method according to claim 15, wherein the anti-oxidant is tocopherol, esters thereof, ascorbic acid, butylhydroxytoluene, butylhydroxyanisole or propyl gallate.
|
Invalid (103)
Entry 75 |
-
Infringement
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Rivastigmine transderma 13.3 mg/24 hrRivastigmine transderma 9.5 mg/24 hrRivastigmine transdermal 4.6 mg/24 hr | US 6,335,031 B1 |
7, 16
|
Infringement
Entry 178
|
Noven Pharmaceuticals
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Rivastigmine transderma 13.3 mg/24 hrRivastigmine transderma 9.5 mg/24 hrRivastigmine transdermal 4.6 mg/24 hr | US 6,335,031 B1 |
7, 16
|
Infringement
Entry 178
|
Noven Therapeutics LLC
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Rivastigmine transderma 13.3 mg/24 hrRivastigmine transderma 9.5 mg/24 hrRivastigmine transdermal 4.6 mg/24 hr | US 6,335,031 B1 |
7, 16
|
Infringement
Entry 178
|
